Aspergillus flavus endocarditis and meningitis in a child with marfan syndrome

Document Type : Case report

Authors

1 Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Pediatrics, Division of Pediatric Infectious Diseases, Ali Asghar Children Hospital, Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

3 Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

10.18502/cmm.6.4.5441

Abstract

Background and Purpose: Aspergillus species are implicated as the etiology of approximately 26% of endocarditis cases. Central nervous system aspergillosis is a life-threatening condition that has a mortality rate of 80%.
Case report: Herein, we report a four– year- old female who was admitted to the pediatric infectious ward due to a fever of unknown origin in January 2020. She was a known case of Marfan syndrome with a family history of this syndrome in her mother. The species was identified using (PCR) and the antifungal susceptibility test was performed using four antifungal agents based on the Clinical and Laboratory Standards Institute M38 3rd edition. Fluconazole-resistant Aspergillus flavus was identified to be responsible for endocarditis and meningitis as well as fever of unknown origin.
Conclusion: The clinicians should be aware and consider fungal endocarditis in blood culture-negative endocarditis even in patients with no significant risk factor when antibiotic therapy fails.
 

Keywords

References

1. Meshaal MS, Labib D, Said K, Hosny M, Hassan M, Al Aziz
SA, et al. Aspergillus endocarditis: diagnostic criteria and predictors of outcome, a retrospective cohort study. PloS One. 2018; 13(8):e0201459.
2. Ghajari A, Lotfali E, Azari M, Fateh R,Kalantary S. Fungal airborne contamination as a serious threat for respiratory infection in the hematology ward. Tanaffos. 2015; 14(4):257-61.
3. Abuzaid AA, Zaki M,Tarif H. Atypical early Aspergillus endocarditis post prosthetic mitral valve repair: a case report. Heart Views. 2015; 16(1):30-3.
4. Soler JAV, Camacho WJM, Rodríguez CXF, Mejía JAN, Guerrero CF,Camacho MAM. Aspergillus flavus endocarditis in an immunocompetent child. Case report. MedMycolCase Rep. 2018; 22:48-51.
5. Millar BC, Jugo J,Moore JE. Fungal endocarditis in neonates and children. Pediatr Cardiol. 2005; 26(5):517-36.
6. Ellis M, Al-Abdely H, Sandridge A, Greer W,Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis. 2001; 32(1):50-62.
7. Dotis J, Iosifidis E,Roilides E. Central nervous system aspergillosis in children: a systematic review of reported cases. Int J Infect Dis. 2007; 11(5):381-93.
8. Denning D W. Invasive aspergillosis. Clin Infect Dis. 1998; 26(4):781-803.
9. Shuper A, Levisky HI,Cornblath DR. Early invasive CNS aspergillosis. An easily missed diagnosis. Neuroradiology. 1991; 33(2):183-5.
10. Antinori S, Corbellino M, Meroni L, Resta F, Sollima S, Tonolini M, et al. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect. 2013; 66(3):218-38.
11. Elsawy A, Faidah H, Ahmed A, Mostafa A,Mohamed F. Aspergillus terreus meningitis in immunocompetent patient: a case report. Front Microbiol. 2015; 6:1353.
12. Nasri T, Hedayati MT, Abastabar M, Pasqualotto AC, Armaki MT, Hoseinnejad A, et al. PCR-RFLP on β-tubulin gene for rapid identification of the most clinically important species of Aspergillus. J Microbiol Methods. 2015; 117:144-7.
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of Filamentous Fungi; approved standard. CLSI document M38. 3rd ed.Wayne, PA: Clinical and Laboratory Standards Institute;2017. P.26.
14. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002; 21(3):240-8.
15. Haßler A, Porto L,Lehrnbecher T. Cerebral fungal infection in pediatric cancer patients. Curr Fungal Infect Rep. 2015; 9(1):6-14.
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med. 2002; 347(6):408-15.
17. Yenişehirli G, Bulut Y, Güven M,Günday E. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens. J Laryngol Otol. 2009; 123(9):978-81.
18. Kammer RB,Utz JP. Aspergillus species endocarditis: the new
face of a not so rare disease. AmJ Med. 1974; 56(4):506-21.
19. Kennedy HF, Simpson EM, Wilson N, Richardson MD, Michie JR. Aspergillus flavus endocarditis in a child with neuroblastoma. J Infect. 1998; 36(1):126-7.
20. Rao K,Saha V. Medical management of Aspergillus flavus endocarditis. Pediatr Hematol Oncol. 2000; 17(5):425-7.
21. Navabi MA, Ajami H, Amirghofran A,Peyravian F. Aspergillus endocarditis: rare but serious Aspergillus ball obstructing the pulmonary artery. EurJ Cardiothorac Surg. 1998; 14(5):530-2.
Current Medical Mycology
Volume 6, Issue 4
December 2020
Pages 70-74

Files

History

  • Receive Date: 24 August 2020
  • Revise Date: 04 November 2020
  • Accept Date: 07 November 2020
  • Publish Date: 01 December 2020

Share

How to cite

Statistics